

## STEP THERAPY CRITERIA

| <b>DRUG CLASS ONLY)</b>     | <b>TOPICAL ANTIFUNGAL AGENTS (BRAND PRODUCTS</b>           |
|-----------------------------|--|
| <b>BRAND NAME (generic)</b> |  |
|                             | <b>ECOZA<br/>(econazole)</b>                               |
|                             | <b>ERTACZO<br/>(sertaconazole)</b>                         |
|                             | <b>EXELDERM<br/>(sulconazole nitrate)</b>                  |
|                             | <b>LOPROX<br/>(ciclopirox shampoo)</b>                     |
|                             | <b>LOTRISONE<br/>(clotrimazole/betamethasone)</b>          |
|                             | <b>LUZU<br/>(luliconazole)</b>                             |
|                             | <b>MENTAX<br/>(butenafine)</b>                             |
|                             | <b>NAFTIN<br/>(naftifine)</b>                              |
|                             | <b>OXISTAT<br/>(oxiconazole)</b>                           |
|                             | <b>VUSION<br/>(miconazole/zinc oxide/white petrolatum)</b> |
|                             | <b>XOLEGEL<br/>(ketoconazole)</b>                          |

Antifungal Topical Step Therapy Policy 06-2017

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). © Registered trademark of the Blue Cross and Blue Shield Association

**Status: CVS Caremark Criteria**

**Type: Initial Step Therapy; Post Step Therapy Prior Authorization**

**POLICY**

**FDA-APPROVED INDICATIONS**

**Ecoza**

Ecoza topical 1% foam is indicated for the treatment of interdigital tinea pedis caused by *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum* in patients 12 years of age and older.

**Ertaczo**

Ertaczo 2% cream is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum*.

**Exelderm**

Exelderm 1% cream is indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Epidermophyton floccosum*, and *Microsporum canis*, and for the treatment of tinea versicolor.

Exelderm 1% solution is indicated for the treatment of tinea cruris and tinea corporis caused by *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Epidermophyton floccosum*, and *Microsporum canis*; and for the treatment of tinea versicolor.

Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting Exelderm solution and clinical improvement usually occurs within one week.

**Loprox**

Loprox 1% shampoo is an antifungal indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.

**Lotrisone**

Lotrisone cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to *Epidermophyton floccosum*, *Trichophyton mentagrophytes*, and *Trichophyton rubrum* in patients 17 years and older.

**Luzu**

Luzu cream is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms *Trichophyton rubrum* and *Epidermophyton floccosum*, in patients 18 years of age and older.

**Mentax**

Mentax 1% cream is indicated for the topical treatment of the dermatologic infection, tinea (pityriasis) versicolor due to *M. furfur* (formerly *P. orbiculare*). Butenafine HCl cream was not studied in immunocompromised patients.

**Naftin**

Naftin 1% gel is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Trichophyton tonsurans*, and *Epidermophyton floccosum*.

Naftin 2% cream is an allylamine antifungal indicated for the treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organism *Trichophyton rubrum*.

Naftin 2% gel is an allylamine antifungal indicated for the treatment of interdigital tinea pedis caused by the organisms *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum*.

### **Oxistat**

Oxistat 1% lotion is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to *Trichophyton rubrum*, *Trichophyton mentagrophytes*, or *Epidermophyton floccosum*.

Oxistat 1% cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to *Trichophyton rubrum*, *Trichophyton mentagrophytes*, or *Epidermophyton floccosum*. Oxistat 1% cream is also indicated for the topical treatment of tinea (pityriasis) versicolor due to *Malassezia furfur*.

### **Vusion**

Vusion ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for *Candida albicans* is not adequate evidence of candidal infection since colonization with *C. albicans* can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment.

Vusion should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Vusion should not be used as a substitute for frequent diaper changes. Vusion should not be used to prevent the occurrence of diaper dermatitis, since preventative use may result in the development of drug resistance.

#### **Limitations of Use**

The safety and efficacy of Vusion have not been demonstrated in immunocompromised patients, or in infants less than 4 weeks of age (premature or term).

The safety and efficacy of Vusion have not been evaluated in incontinent adult patients. Vusion should not be used to prevent the occurrence of diaper dermatitis, such as in an adult institutional setting, since preventative use may result in the development of drug resistance.

### **Xolegel**

Xolegel is indicated for the topical treatment of seborrheic dermatitis in immunocompetent adults and children 12 years of age and older.

Safety and efficacy of Xolegel for treatment of fungal infections have not been established.

### **INITIAL STEP THERAPY**

If the patient has filled a prescription for a 7 day supply of a generic topical antifungal agent within the past 120 days under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

## **COVERAGE CRITERIA**

The requested drug will be covered with prior authorization when the following criteria are met:

- The patient experienced an inadequate treatment response, intolerance, or contraindication to a generic topical antifungal agent (e.g., ciclopirox, clotrimazole, ketoconazole, naftifine, oxiconazole)

## **REFERENCES**

1. Ecoza [package insert]. Florham Park, NJ: Exeltis USA Dermatology LLC. July 2016.
2. Ertaczo [package insert]. San Antonio, TX: DPT Laboratories, Ltd., January 2014.
3. Exelderm1% cream [package insert]. Jacksonville, FL: Ranbaxy Laboratories Inc. July 2013.
4. Exelderm1% solution [package insert]. Jacksonville, FL: Ranbaxy Laboratories Inc. March 2013.
5. Loprox 1% shampoo [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC. February 2017.
6. Lotrisone [package insert]. Whitehouse Station, NJ: Merck & Co., Inc. September 2015.
7. Luzu cream [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; February 2017.
8. Mentax [package insert]. Morgantown, WV: Mylan Pharmaceutical Inc. November 2013.
9. Naftin 1% gel [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; April 2013.
10. Naftin 2% cream [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; October 2014.
11. Naftin 2% gel [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; October 2014.
12. Oxistat1% cream/lotion [package insert]. Melville, NY: Fougera Pharmaceuticals Inc., LLC; January 2012.
13. Vision [package insert]. Newtown, PA: Prestium Pharma, Inc. October 2013.
14. Xolegel [package insert]. West Chester, PA: Aqua Pharmaceuticals. September 2013.
15. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; [http://online.lexi.com/lco/action/index/dataset/complete\\_ashp](http://online.lexi.com/lco/action/index/dataset/complete_ashp) [available with subscription]. Accessed June 2017.
16. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. [www.micromedexsolutions.com](http://www.micromedexsolutions.com) [available with subscription]. Accessed June 2017.
17. Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and Management of Tinea Infections. *Am Fam Physician*. 2014;90(10):702-710.
18. Clark GW, Pope SM, Jaboori KA. Diagnosis and Treatment of Seborrheic Dermatitis. *Am Fam Physician*. 2015;91(3):185-190.
19. Clunk C, Domingues E, Wiss K. An Update on Diaper Dermatitis. *Clinics in Dermatology*. 2014;32(4):477-487. Available at: <http://dx.doi.org/10.1016/j.clindermatol.2014.02.003>